Cingulate is trading 5.7% lower at $4.61, with no corroborated catalyst for the October 12 pre-market decline.
- The stock closed at $4.89 on October 9.
- The latest readily identifiable company news was an October 2 notice extending the chief medical officer’s trial employment period. Roth Capital’s reported price-target reduction to $9 followed the Q2 report and was not a new overnight event.
- The healthcare sector is indicated higher, which does not explain Cingulate’s decline.